Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475660 | 1.00 | CYP1A2 (0.33) | CYP1A2HIF1APPM1BPTPN1PPP1CC | |
| SCHEMBL14649971 | 1.00 | CYP1A2 (0.33) | CYP1A2HIF1APPM1BPTPN1PPP1CC | |
| SCHEMBL14915676 | 0.81 | PDK1 (0.38) | PPM1BPTPN1PPP1CCKDM4EGAA | |
| SCHEMBL8752895 | 0.81 | PDK1 (0.38) | PPM1BPTPN1PPP1CCKDM4EGAA | |
| SCHEMBL24664101 | 0.80 | CYP1A2 (0.33) | CYP1A2HIF1APPM1BPTPN1PPP1CC | |
| SCHEMBL19386329 | 0.80 | CYP1A2 (0.33) | CYP1A2HIF1APPM1BPTPN1PPP1CC | |
| SCHEMBL433180 | 0.78 | POLB (0.33) | CYP1A2HIF1APPM1BPTPN1PPP1CC | |
| SCHEMBL24664106 | 0.78 | POLB (0.33) | CYP1A2HIF1APPM1BPTPN1PPP1CC | |
| SCHEMBL907524 | 0.78 | POLB (0.33) | CYP1A2HIF1APPM1BPTPN1PPP1CC | |
| SCHEMBL31264948 | 0.78 | CYP2C19 (0.42) | CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ABAC Therapeutics, S.L. (ES) | 2021-02-16 | — | — | US | disclosed |
| EP-3490984-B1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | Abac Therapeutics Sl (ES) | 2020-09-09 | — | — | EP | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC Therapeutics, S.L. (ES) | 2019-06-13 | — | — | US | disclosed |
| EP-3490984-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | Abac Therapeutics, S.L (ES) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020004-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC THERAPEUTICS, S.L (ES) | 2018-02-01 | — | — | WO | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BILCER GEOFFREY M (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120214802-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2012-08-23 | — | — | US | disclosed |
| EP-2486006-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2411000-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2349244-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011044057-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010110817-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010042892-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ATAD2, ATAD2B, ATAD5 | CYP1A2 547/4885HIF1A 980/4885PPM1B 94/4885 |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, GSAP | CYP1A2 4674/4885HIF1A 4028/4885PPM1B 485/4885 |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CYP1A2 4473/4885HIF1A 3527/4885PPM1B 547/4885 |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ATAD2, ATAD2B, ATAD5 | CYP1A2 547/4885HIF1A 980/4885PPM1B 94/4885 |
| US-20120214802-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CYP1A2 4473/4885HIF1A 3527/4885PPM1B 547/4885 |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CYP1A2 4473/4885HIF1A 3527/4885PPM1B 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.